logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q3 2018
Strongbridge Biopharma plc
Topline data from Phase 3 study of COR-003 (LOGICS)
endogenous Cushing's syndrome
2H 2018
BioLineRx Ltd.
Topline results from phase 2a study of BL-8040 with Keytruda
pancreatic cancer
2H 2018
ALDER BIOPHARMACEUTICALS INC
Filing of a BLA with the FDA for Eptinezumab (formerly ALD 403)
prevention of migraine
2H 2018
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-PH)
Liver cirrhosis caused by nonalcoholic steatohepatitis
2H 2018
Endocyte, Inc.
Updated results from Peter MacCallum Cancer Center-sponsored 177Lu-PSMA-617 trial
Metastatic castration-resistant prostate cancer
2H 2018
Xenon Pharmaceuticals Inc.
Phase I read-out XEN901 (UK)
Epilepsy
2H 2018
BioLineRx Ltd.
Topline results from Phase 2a trial of BL-8040 (COMBAT Study)
Metastatic pancreatic cancer
2H 2018
OncoMed Pharmaceuticals Inc
Interim data from 1st phase 1b dose escalation and expansion studies of Navicixizumab
Platinum-resistant ovarian cancer
2H 2018
OncoMed Pharmaceuticals Inc
Interim data from 2nd phase 1b dose escalation and expansion studies of Navicixizumab
Metastatic colorectal cancer
Q3 2018
Progenics Pharmaceuticals Inc
Top-line data from phase III study of 1404
Prostate cancer
2H 2018
Tesaro Inc.
Data from Phase 2 trial in combination with anti-PD-1 of niraparib (AVANOVA)
Recurrent ovarian cancer
2H 2018
ASSEMBLY BIOSCIENCES, INC.
Initial POC HBV clinical data
Chronic hepatitis B infections
2H 2018
Proteostasis Therapeutics, Inc.
Initial results from triple combination study of PTI-428, PTI-801 and PTI-808
Cystic Fibrosis
2H 2018
Arsanis, Inc.
Top line safety and efficacy results from phase II study of ASN100
Staphylococcus aureus Pneumonia
2H 2018
Syndax Pharma
Data from phase 1 multiple ascending dose (MAD) clinical trial of SNDX-6352
Solid tumors
2H 2018
Five Prime Therapeutics
Updates from phase 1a/1b trial of Cabiralizumab in combination with Opdivo
Late-line pancreatic cancer
2H 2018
BioXcel Therapeutics, Inc.
Data from Phase 1b pharmacokinetic/pharmacodynamic (PK/PD) safety study using IV formulation of Dex (BXCL501)
Mild probable Alzheimer's Disease
2H 2018
BioXcel Therapeutics, Inc.
Data from Phase 1b PK/PD safety study using IV formulation of Dex (BXCL501)
Schizophrenia
2H 2018
Heron Therapeutics Inc.
Submission of NDA for HTX-011
Bunionectomy And Hernia Repair
Q3 2018
Geron Corporation
Primary analysis of phase II study of Imetelstat (IMbark)
Intermediate-2 or high-risk myelofibrosis
2H 2018
Apellis Pharmaceuticals, Inc.
Data from phase II proof of concept monotherapy data for APL-2 in four types of nephropathies
IgA nephropathy, C3 glomerulonephropathy, primary membranous nephropathy, and lupus nephritis
2H 2018
Xtant Medical Holdings, Inc
Human proof-of-concept data from phase I clinical trial of DCR-PHXC
Primary hyperoxaluria
2H 2018
Zealand Pharma A/S
Results from pivotal phase III efficacy trial of Dasiglucagon
Severe hypoglycemia
2H 2018
Arbutus Biopharma Corp.
Interim on-treatment results from phase II triple combination study of ARB-1467, tenofovir and pegylated interferon
HBV
2H 2018
Insys Therapeutics, Inc.
Data read for phase II study of cannabidiol (CBD) oral solution
Childhood absence epilepsy